Latest Conference Articles

Tumor Burden Limits Liver Transplant Feasibility for HCC

Researchers have uncovered an upper limit in tumor burden after which there is a lower probability of successfully downstaging patients with hepatocellular carcinoma for liver transplantation.

Dr. Long on Treating Melanoma With Dabrafenib Plus Trametinib

Georgina V. Long, BSc, PhD, MBBS, chair of Melanoma Medical Oncology and Translational Research at the Melanoma Institute of Australia (MIA) and Royal North Shore Hospital, University of Australia, discusses the patients with melanoma who respond best to the combination of dabrafenib plus trametinib.

Multidisciplinary Care Associated With Improved OS for HCC Patients

Multidisciplinary tumor boards led to higher utilization of guideline-recommended curative therapies, which was associated with improved overall survival for patients with early-stage hepatocellular carcinoma.

Optimizing Frontline Immunotherapy in NSCLC

Immunotherapy continues to revolutionize the field of non–small cell lung cancer, with researchers now focusing on the optimal use of immune agents in the frontline setting.

Expert Discusses Next Steps With Immunotherapy in Lung Cancer

Hossein Borghaei, DO, discuss what lies ahead for immunotherapy in lung cancer, and what changes may be on the horizon for such agents as pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy) in the frontline setting.

Using PD-L1 Expression to Determine Lung Cancer Treatments

Standard of care for newly diagnosed non-small cell lung cancer is shifting to include PD-L1 expression to determine the appropriate treatment plan, says Matthew D. Hellmann, MD.

Dr. Montano-Loza on Link Between HCC Risk and High Visceral Adipose Tissue

Aldo J. Montano-Loza, MD, MSc, PhD, associate professor of medicine, program director of hepatology, gastroenterology rotation supervisor, University of Alberta, discusses the link between high visceral adipose tissue and hepatocellular carcinoma risk in patients with cirrhosis.

DAAs Not Associated With Increased HCC Risk in HCV Patients

Treatment with direct-acting antiviral therapy did not increase the risk of developing hepatocellular carcinoma in patients with hepatitis C virus (HCV) infection.

Researchers Validate Novel Prediction Index for HCC After Liver Transplant

A new system for gauging the probability for hepatocellular carcinoma recurrence following liver transplant surgery has proved successful.

Dr. Halmos on MET Mutations in Patients With NSCLC

Balazs Halmos, MD, director, Thoracic Oncology, director, Clinical Cancer Genomics, Montefiore Medical Center, discusses the prevalence of MET mutations in patients with non–small cell lung cancer (NSCLC).

Dr. Naveed Zafar Janjua on Impact of Hepatitis C Treatment Timing on HCC Risk

Naveed Zafar Janjua, MBBS, MSc, DrPH, senior scientist, clinical prevention services, BC Centre for Disease Control and clinical associate professor, School of Population and Public Health, University of British Columbia, discusses the findings from the British Columbia hepatitis testers cohort, which looked at the impact of hepatitis infection on long term risk of hepatocellular carcinoma (HCC).

Dr. West on Considering Factors for EGFR TKIs in NSCLC

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses factors he takes into consideration for EGFR tyrosine kinase inhibitors in patients who have EGFR-positive non–small cell lung cancer (NSCLC).

Regorafenib Renews Hope in Hepatocellular Carcinoma

There has been renewed optimism in hepatocellular carcinoma with regorafenib, a novel second-line agent that is currently being considered for approval by the FDA.

Preclinical Studies Help to Illuminate Immunotherapy's Role in HCC

Following on their impressive success in the treatment of several other tumor types, immune-based therapies are being studied in clinical trials for hepatocellular carcinoma and are showing promising signals of efficacy.

Percutaneous and Laparoscopic RFA Outcomes Similar for HCC

Similar recurrence-free survival was demonstrated with radiofrequency ablation using percutaneous and laparoscopic methods for patients with hepatocellular carcinoma who were eligible for ablation.

Dr. Tim F. Greten on Immunotherapy in HCC

Tim F. Greten, MD, senior investigator thoracic and gastrointestinal oncology branch, head, gastrointestinal malignancy section, National Cancer Institute (NCI), discusses the potential for immunotherapy in hepatocellular carcinoma (HCC).

Dr. Hashem El-Serag on the Relationship Between NASH and HCC

Hashem El-Serag, MD, MPH, medicine-gastroenterology, Baylor College of Medicine, discusses the relationship between nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC).

Biomarkers Define Future Age of Immunotherapy in Cancer

The use of immunotherapy as a treatment for cancer is progressively increasing with a flood of recent approvals for immune checkpoint inhibitors directed against CTLA-4 and PD-1.

Lack of Screening, Surveillance Leads to Rising HCC Rates in Hepatitis B Patients

Hepatocellular carcinoma‎ incidence continues to rise among patients with hepatitis B despite improvements in antiviral therapies, stressing the importance of screening and surveillance in this population.

Dr. George N. Ioannou on the Efficacy of Antiviral Agents for Hepatitis C in HCC Patients

​George N. Ioannou, MD, associate professor, VA Puget Sound Health Care System, University of Washington School of Medicine, discusses a study evaluating the effectiveness of direct antiviral agents for hepatitis C virus patients with hepatocellular carcinoma (HCC).

Pembrolizumab OS Benefit Sets New Benchmark in Second-Line Bladder Cancer

Pembrolizumab monotherapy reduced the risk of death by 27% compared with chemotherapy for patients with advanced urothelial carcinoma whose disease progressed after prior treatment.

Lirilumab/Nivolumab Combo Highly Effective in Head and Neck Cancer

The combination of lirilumab and nivolumab resulted in an objective response rate of 24.1% in patients with squamous cell carcinoma of the head and neck.

Emerging Data Could Rearrange Frontline EGFR TKIs in NSCLC

Individualizing frontline therapy for patients with non–small cell lung cancer based on preferences and clinical experience, as well as efficacy and safety data from pivotal trials, is an appropriate method for selecting EGFR-targeted agents.

Therapeutic Options Expanding for ALK-Rearranged NSCLC

The treatment landscape for patients with ALK-rearranged non–small cell lung cancer is changing rapidly, gearing up the potential for more therapeutic options to address the heterogeneity of the mechanism of resistance in this population.

Dr. Perez-Soler on Impact of Osimertinib on Field of NSCLC

Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, Albert Einstein College of Medicine of Yeshiva University, discusses the impact of osimertinib (Tagrisso) on patients with T790M-positive non–small cell lung cancer (NSCLC).

Dr. Anne Chiang on Molecular Testing in Lung Cancer Treatment Planning

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses molecular testing in lung cancer and how it affects treatment decisions.

ERK Inhibition May Explain Regorafenib Success in Sorafenib-Resistant HCC

Efforts are under way to further evaluate the effects of regorafenib on sorafenib-resistant HCC cells, including the role of suppressing the ERK signaling pathway.

Dr. Bellmunt Shares KEYNOTE-045 Data for Pembrolizumab Versus Chemotherapy in Bladder Cancer

Joaquim Bellmunt, MD, PhD, attending physician of Solid Tumor Oncology at Dana-Farber Cancer Institute, discusses findings from the phase III KEYNOTE-045 study, which compared second- or third-line pembrolizumab with investigator-choice chemotherapy as a treatment for patients with metastatic or locally advanced, unresectable urothelial carcinoma.

Dr. Gonzalez on Cost-Benefit of Treating Hepatitis C in HCC Patients Before Transplant

Stevan A. Gonzalez, MD MS, clinical assistant professor, department of internal medicine, Texas A&M College of Medicine, medical director of liver transplantation, Simmons Transplant Institute, Baylor All Saints Medical Center, discusses a cost effectiveness analysis of treating hepatitis C patients with hepatocellular carcinoma (HCC) before or after a liver transplant.

Explosion of Novel Agents, Liquid Biopsies Leading Advancements in Lung Cancer Field

Lung cancer treatment has undergone a game-changing transformation within the past few years, with a burst of FDA approvals of targeted agents and immunotherapies across a number of indications.